Augmentation of EMDR With MtCS in the Treatment of Fibromyalgia
Fibromyalgia, Psychological Trauma, Depressive Symptoms
About this trial
This is an interventional treatment trial for Fibromyalgia focused on measuring Fibromyalgia, Psychological trauma, Posttraumatic stress disorder, Major depressive disorder, Anxiety disorder, Eye Movement Desensitization and Reprocessing, Multifocal transcranial Current Stimulation
Eligibility Criteria
Inclusion Criteria:
- Age between 18 and 70 years old
- Mean pain score of at least 4 on the visual analog scale (VAS) in the two weeks preceding the clinical trial
- Presence of one or more traumatic events causing current trauma-related symptoms
- Current clinical symptoms of depression and/or anxiety
- 2 weeks of stable medication
Exclusion Criteria:
- Comorbid autoimmune or chronic inflammatory disease
- Neurological or serious medical diseases
- Bipolar disorder, schizoaffective disorder and schizophrenia
- Suicidal ideation
- Previous EMDR therapy
- Substance abuse/dependency within 1 month prior to participation (except for nicotine abuse/dependency),
- Pending FM-related litigation or disability
- Metallic implants in the head
- Positive test for pregnancy
Sites / Locations
- Centre Forum (Parc de Salut Mar)
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Placebo Comparator
No Intervention
EMDR plus MtCS
EMDR plus sham-MtCS
Treatment as Usual
MtCS stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions.
Sham stimulation will consist of inactive MtDCS for 20 minutes applied immediately before EMDR sessions
Patients in this condition will not receive EMDR nor MtCS sessions, and will continue to attend their regular visits with rheumatology and psychiatry. The patients from the TAU group will have the choice to attend 10 sessions of EMDR group therapy when the research project finishes.